Full Papers
Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis
Q. Zhou1, S. Zhu2, S. Dai3, Q. Wu4, J. Zheng5, H. Zhu6, W. Yang7
- Emergency Medical Center, Ningbo Yinzhou no. 2 Hospital, Ningbo, Zhejiang, China. lfsgjytg@163.com
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Zhejiang Chinese Medical University
CER18234
Full Papers
PMID: 39977004 [PubMed]
Received: 15/10/2024
Accepted : 15/01/2025
In Press: 13/02/2025
Abstract
OBJECTIVES:
Rheumatoid arthritis (RA) is a prevalent autoimmune disorder. This study examines the comparative efficacy of Janus kinase inhibitors (JAKi) and adalimumab (ADA) in managing RA.
METHODS:
As of May 2024, four electronic databases were systematically reviewed: PubMed, Web of Science, Embase, and the Cochrane Library. Data were analysed using Review Manager (RevMan) software. The risk ratio (RR) and its 95% confidence interval (CI) represented dichotomous outcomes. Evaluated outcome measures included ACR20, ACR50, ACR70, Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and Disease Activity Score 28-4 (C-reactive protein) (DAS28-4(CRP)).
RESULTS:
The analysis encompassed 6 studies, totalling 4048 patients with RA. There was no statistically significant difference in efficacy between JAKi and ADA when assessing ACR20 (p=0.25) and DAS28-4(CRP) (p=0.57). However, JAKi demonstrated superior efficacy compared to ADA for ACR50 (RR=1.20; p=0.02), ACR70 (RR=1.24; p=0.03), CDAI (RR=1.17; p=0.01), and SDAI (RR=1.19; p=0.006) outcomes. Longitudinal analysis revealed that over a 52-week period, JAKi did not exhibit superior efficacy to ADA for ACR50 (RR=1.16; p=0.19) and ACR70 (RR=1.10; p=0.26). Specifically, the tofacitinib subgroup outperformed ADA (RR=1.49; p=0.003), while other JAKi treatments did not show a significant difference (RR=1.19; p=0.11) compared to ADA.
CONCLUSIONS:
JAKi generally offers better efficacy than ADA in the treatment of RA, though this advantage appears to be influenced by the duration of treatment.
